MedTrace Logo

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

NCT04202978 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-04-16

No results posted yet for this study

Summary

To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation

Conditions

  • Hepatic Metastasis of Colorectal Cancer

Interventions

DRUG

Camrelizumab

Camrelizumab ：200mg intravenous injection d1 q3w

DRUG

Apatinib Mesylate

Apatinib：250mg/d P.O ,qd ,3weeks

DRUG

Capecitabine

capecitabine:850mg/m2 P.O ,bid ,d1-d14

DRUG

Oxaliplatin

oxaliplatin:130mg/m2 intravenous injection d1 q3w

RADIATION

radiofrequency ablation

radiofrequency ablation:between first cycle and second cycle percutaneous

Sponsors & Collaborators

  • Zhongshan Hospital Xiamen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2021-03-01
Completion
2021-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202978 on ClinicalTrials.gov